Tu1846 PHASE 2A PROOF OF CONCEPT PLACEBO CONTROLLED STUDY WITH ORAL ABX464 50MG QD IN ULCERATIVE COLITIS SHOWS ENDOSCOPIC IMPROVEMENT WITH LOSS OF MICROSCOPIC DISEASE ACTIVITY IN MOST ENDOSCOPIC RESPONDERS

adenomas (9.2%) compared to matched controls (3.8%), which was statistically significant (p=0.034;adjusted OR 2.379; 95% CI: 1.067 -5.303).SOT recipients with negative baseline screening colonoscopy had more advanced CA (villous histology, size ‡ 10 mm, more than 3 polyps, presence of dysplasia) but those differences reflected a trend that failed to reach statistical significance.Conclusion: SOT recipients who are otherwise average risk appear at higher risk for developing larger advanced CA.These findings support a strategy for earlier and more frequent colonoscopic surveillance in SOT recipients, despite the absence of advanced histologic features.